Dr. Mengyu Lu leads Kirkland & Ellis's Asia capital markets practice from its Hong Kong office. With a specialization in Hong Kong IPOs, SPACs, pre-IPO financings, follow-on offerings, M&A, and post‑listing compliance, she is a trusted legal advisor to issuers, investment banks, private equity and venture capital firms across the region.
Her expertise notably spans the "new economy" sectors-healthcare, biotech, semiconductors, AI, TMT, and consumer-working with clients like NIO, Will Semiconductor, Kelun Biotech, Super Hi, ZG Group, and more.
Dr. Lu began her legal journey at Freshfields Bruckhaus Deringer (2008–2010), joined Kirkland & Ellis in 2011, made partner in 2014, moved to Sidley Austin (2015–2021), and re-joined Kirkland in early 2021.
A distinguished capital markets specialist with a Ph.D., Dr. Mengyu Lu combines academic depth, elite law firm experience, and landmark deal credentials. As one of Asia's leading lawyers in equity and debt markets, she continues to shape the region's capital market landscape, forging transformative public listings and financing deals.
FIRM PROFILE
Kirkland & Ellis LLP is a leading global law firm renowned for its dominance in private equity, M&A, restructuring, litigation, intellectual property, and executive compensation. Founded in 1909 and headquartered in Chicago, the firm has grown into a powerhouse with over 3,500 lawyers across 21 offices worldwide, including key locations in New York, London, Hong Kong, and Riyadh.
Core Practice Areas
Private Equity & M&A: Kirkland's market-leading transactional teams advise on leveraged buyouts, complex corporate mergers, carve-outs, and cross-border deals, serving both sponsors and strategic acquirers.
Restructuring & Insolvency: With over 200 dedicated attorneys in U.S., London, Munich, and Hong Kong, the firm is globally recognized-Ranked #1 in global restructuring for eight consecutive years.
Litigation & Dispute Resolution: The firm operates a formidable trial-ready litigation department handling high-stakes commercial, IP, antitrust, and white-collar matters, with a top-tier success record.
Intellectual Property: Kirkland offers deep bench strength in patent, trademark, trade-secret cases, and technology-driven disputes, leveraging cross-disciplinary transactional counsel as needed.
Executive Compensation, Employment & Benefits: The team supports clients through M&A, spinoffs, restructurings, and IPOs-designing tailored compensation plans while navigating the evolving regulatory landscape.
Kirkland & Ellis stands as a top-tier global firm- unmatched in transaction execution, litigation prowess, and legal innovation-powered by a globally integrated platform and a dynamic, client-focused culture.
DEAL REPORT:
Kirkland & Ellis represented Edding Group Company Limited-a PRC-based integrated biopharmaceutical company focused on R&D and commercialization-in its proposed merger and reverse takeover of Genor Biopharma Holdings Limited, a Chapter 18A–listed oncology and immunology-focused biotech firm on the Hong Kong Stock Exchange. Announced in early October 2024, this transaction marks the first-ever Chapter 18A reverse takeover in Hong Kong and the only such deal publicly disclosed in the market at the time.
The merger is designed to create compelling complementary capabilities between the two businesses: Edding brings deep commercialization know-how and a broad product portfolio in anti-infectives and respiratory therapies, complemented by Genor's innovative oncology and immunology pipeline under Chapter 18A . The combination is expected to establish a more robust industrial model, fully integrating R&D, production, and sales, while offering Edding a backdoor listing into Hong Kong.
The Kirkland team was led by capital markets partner Dr. Mengyu Lu, alongside corporate partners Joey Chau, Ashlee Wu, and Leo Zhou, and supported by associates Chuanwen Wang, Rock Liu, and registered foreign lawyer Sherry Fu.
